Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data.
In this third episode of the Quarterly Focus on Genitourinary Cancer, two pivotal, international publications on Bladder Cancer from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications.
The expert panel consist of:
Niven Mehra, MD, PhD – medical oncologist, Radboudumc, Nijmegen
Andre Bergman, MD, PhD – medical oncologist, Netherlands Cancer Institute, Amsterdam
Prof. Theo de Reijke, MD - urologist, Amsterdam UMC, Amsterdam
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer (LATITUDE)
N Engl J M, July 27, 2017
Speaker: Karim Fizazi, MD, PhD - medical oncologist, Gustave Roussy Institute, Villejuif, France
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
The Lancet, Oct 21, 2018
Speaker: Prof. Nicholas James, PhD - medical oncologist, University of Birmingham, UK